- Home
- TSHA
as 07-26-2024 4:00pm EST
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 439.0M | IPO Year: | 2020 |
| Target Price: | $6.60 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $4.32 | Next Earning Date: | 08-12-2024 |
| Revenue: | $14,156,000 | Revenue Growth: | 96.39% |
| Revenue Growth (this year): | -23.47% | Revenue Growth (next year): | -48.92% |
Stock Insider Trading Activity of Taysha Gene Therapies Inc. (TSHA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Manning Paul B | TSHA | 10% Owner | Nov 17 '23 | Buy | $1.63 | 100,000 | $163,000.00 | 16,566,667 | SEC Form 4 |
Latest Taysha Gene Therapies Inc. News
TSHA Breaking Stock News: Dive into TSHA Ticker-Specific Updates for Smart Investing
GlobeNewswire
22 days ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Argus Research
25 days ago
Daily – Vickers Top Buyers & Sellers for 07/02/2024
Simply Wall St.
25 days ago
Insider Buyers At Taysha Gene Therapies Sitting On US$24m Profit
MT Newswires
25 days ago
Taysha Gene Therapies Insider Bought Shares Worth $2,999,999, According to a Recent SEC Filing
MT Newswires
a month ago
BMO Initiates Taysha Gene Therapies at Outperform With $5 Price Target
MT Newswires
a month ago
Taysha Gene Therapies Prices $75 Million Offering of Shares, Pre-Funded Warrants; Shares Fall
GlobeNewswire
a month ago
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
MT Newswires
a month ago
Top Premarket Decliners
Compare TSHA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TSHA Taysha Gene Therapies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.